NOWDiagnostics Raises $22.5M In Series B Financing Led By DigitalDx Ventures
Funds To Accelerate Development And Expansion Of At-Home Diagnostic Solutions; Investors Include Labcorp Venture Fund And Kompass Kapital Management
Funds To Accelerate Development And Expansion Of At-Home Diagnostic Solutions; Investors Include Labcorp Venture Fund And Kompass Kapital Management
Date | Price Target | Rating | Analyst |
---|---|---|---|
3/25/2024 | $250.00 | Hold → Buy | Argus |
2/26/2024 | $260.00 | Outperform | Leerink Partners |
2/9/2024 | $240.00 | In-line | Evercore ISI |
1/3/2024 | $222.00 | Equal Weight | Barclays |
9/6/2023 | $210.00 | Hold | HSBC Securities |
12/12/2022 | $275.00 → $250.00 | Buy → Neutral | Citigroup |
9/19/2022 | Buy → Hold | Argus | |
8/22/2022 | $300.00 | Overweight | Morgan Stanley |
BURLINGTON, N.C., Sept. 16, 2024 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH) (Labcorp) announced today that its wholly owned subsidiary, Laboratory Corporation of America Holdings (LCAH), has priced its offering of $2,000,000,000 in senior notes (the Offering). The Offering consists of three tranches: $650,000,000 aggregate principal amount of 4.350% Senior Notes due 2030 (the 2030 Notes), $500,000,000 aggregate principal amount of 4.550% Senior Notes due 2032 (the 2032 Notes) and $850,000,000 aggregate principal amount of 4.800% Senior Notes due 2034 (the 2034 Notes and, together with the 2030 Notes and the 2032 Notes, the Notes). The Notes will bear interest from September 23, 2024, pa
Enhances Labcorp's laboratory services network and expands access to its clinical services BURLINGTON, N.C. and MIAMI, Sept. 16, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (NASDAQ:OPK), a multinational biopharmaceutical and diagnostics company, announced today the completion of Labcorp's acquisition of select assets of BioReference Health, a wholly owned subsidiary of OPKO Health. The transaction is expected to provide patients, physicians and customers with greater access to Labcorp's comprehensive, high-quality laboratory services, scientific expertise and expanded testing capabilities in key regions a
BURLINGTON, N.C., Sept. 3, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that members of the executive management team will participate in a presentation at the Baird 2024 Global Healthcare Conference on Tuesday, September 10, at 3:10 p.m. ET. About LabcorpLabcorp (NYSE:LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science
- Reuters
-Reuters
Evercore ISI Group analyst Elizabeth Anderson maintains Labcorp Holdings (NYSE:LH) with a In-Line and raises the price target from $210 to $215.
4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
IRVINE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, proudly announces the appointment of Gary Huff to its Strategic Advisory Board (SAB). Mr. Huff, former CEO of Diagnostics at Laboratory Corporation of America Holdings, "LabCorp" (NYSE:LH), brings extensive expertise to collaborate with Jack Kenny, Chairman of Biomerica, and Zack Irani, CEO of Biomerica, in driving expansion of the inFoods® IBS product. Most recently, Mr. Huff served as the CEO of LabCorp Diagnostics, overseeing one of the world's largest diagnostics clinical laboratories, boasting $7B in annual revenues, ov
SAN DIEGO, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the appointment of Marcia Eisenberg, Ph.D., to the Company's Board of Directors. Dr. Eisenberg currently serves as Senior Vice President and Enterprise Chief Scientific Officer at Labcorp (NYSE:LH) and brings more than 30 years of experience with molecular genetics, DNA testing, biotechnology, and molecular oncology. "Marcia's deep and diverse genomics expertise will be an asset to Singular as we drive our business strategy forward, and we are delighted to w
Health system executive brings three decades of medical enterprise experience to Labcorp BURLINGTON, N.C., June 7, 2023 /PRNewswire/ -- Labcorp (NYSE:LH), a leading global life sciences company, today announced the appointment of Dr. Paul Rothman to its Board of Directors as an independent member. Dr. Rothman's appointment is effective June 6, 2023, at which time the Board will expand to 12 directors, 11 of whom are independent. "I am pleased to announce Dr. Rothman's appointment to our Board of Directors," said Adam Schechter, chairman and chief executive officer (CEO) of Lab
Updates Full-Year Guidance Results from Continuing Operations for second quarter 2024 versus last year:Revenue: $3.22 billion versus $3.03 billionDiluted EPS: $2.43 versus $1.74Adjusted EPS: $3.94 versus $3.42Free Cash Flow: $432.9 million versus $58.2 millionUpdated Full-Year 2024 Guidance:Revenue range of 6.4% to 7.5%, includes Invitae impact of ~1.0%Adjusted EPS range of $14.30 to $14.90, includes Invitae dilution of ~$0.40Free Cash Flow of $0.85 billion to $1.00 billion, includes Invitae cash usage of ~$150 millionShare repurchase authorization increased by $1.0 billion to $1.4 billionLaunched important new tests in specialty testing areasIntroduced Labcorp Global Trial Connect, a suite
BURLINGTON, N.C., July 25, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on September 13, 2024, to stockholders of record as of the close of business on August 29, 2024. About Labcorp Labcorp (NYSE:LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident de
BURLINGTON, N.C., July 1, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the second quarter of 2024 before the market opens on Thursday, August 1, 2024. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Participants may also re
FWP - LABCORP HOLDINGS INC. (0000920148) (Subject)
8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
Argus upgraded Laboratory Corp from Hold to Buy and set a new price target of $250.00
Leerink Partners initiated coverage of Laboratory Corp with a rating of Outperform and set a new price target of $260.00
Evercore ISI initiated coverage of Laboratory Corp with a rating of In-line and set a new price target of $240.00
SC 13G/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Subject)
SC 13D/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Filed by)
SC 13G/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Subject)